Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 269
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Natural history/Epidemiology, Treatment
Active
18 and over
Pharmaceutical / Industry
U2963n
NCT00097565
2.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
12 to 55
Pharmaceutical / Industry
GC P#02.01.001
NCT00469729
Last Modified:
6/9/2008
 
First Published:
9/26/2007
3.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
4 and over
NCI
RPCI-I-72806
I 72806, NCT00536601
4.
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care, Treatment
Active
18 to 75
Other
0705-20 IUCRO-0196
NCT00594308
5.
Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
19 to 70
Other
F080429003
UAB-0775, NCT00714259
Last Modified:
8/21/2008
 
First Published:
12/22/2004
6.
Phase III Randomized Study of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Single Agent Therapy in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
UCLA-0406049-01
CTI-PIX301, NCT00101049
7.
Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 78
Pharmaceutical / Industry
AMD3100-3101
NCT00103610
Last Modified:
10/24/2008
 
First Published:
6/25/2005
8.
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
CALGB-50303
CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209
9.
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
9823
H6Q-MC-JCBJ, PRELUDE, NCT00332202
10.
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 to 80
NHLBI
384
BMT CTN 0401, U01 HL069294-05, NCT00329030
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute